The HemOnc Pulse cover image

Sagar Lonial, MD, FACP, on Why This MRD Approach Is ’Premature’ in MM

The HemOnc Pulse

00:00

How to Define High-Risk Smoldering Myeloma

How do you define high-risk smoldering myeloma? And then I know a lot of folks are saying, you don't treat outside of a clinical trial. Well, the challenge with many of the large randomized trials is that we keep moving the definition. So understanding which patients really got benefit from early intervention sometimes becomes a little challenging. High risk means your risk of progressing to symptomatic myeloma within two years is between 50 and 70%.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app